Stoke Therapeutics (STOK) Retained Earnings (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Retained Earnings of -$115000.0 for Q1 2026, up 99.97% year-over-year from -$57508.7 in Q1 2025, and down 121.18% quarter-over-quarter from $543000.0 in Q4 2025.
Stoke Therapeutics (STOK) Retained Earnings (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$115000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.97% year-over-year to -$115000.0; the TTM figure through Mar 2026 stood at -$115000.0 (up 99.97% YoY), while the FY2025 annual figure was $543000.0, down 99.92% from the prior year.
- Retained Earnings for Q1 2026 stood at -$115000.0, down from $543000.0 in the prior quarter.
- The five-year high for Retained Earnings was $720.0 million in Q4 2024, with the low at -$439.8 million in Q3 2025.
- The 5-year median for Retained Earnings is -$24000.0 (2023), against an average of $54.1 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings sank 1233968.18% in 2022, then soared 3000087.5% in 2024.
- Stoke Therapeutics' Retained Earnings stood at -$1.2 million in 2022, then soared by 97.96% to -$24000.0 in 2023, then jumped by 3000087.5% to $720.0 million in 2024, then plunged by 99.92% to $543000.0 in 2025, then plunged by 121.18% to -$115000.0 in 2026.
- Business Quant data shows STOK's Retained Earnings at -$115000.0 in Q1 2026, $543000.0 in Q4 2025, and -$439.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 955.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 955.42 Mn |
| Mar 31, 2026 | -115,000.00 |
| Dec 31, 2025 | 543,000.00 |
| Sep 30, 2025 | -439.78 Mn |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | -377.95 Mn |
| Dec 31, 2024 | 720.00 Mn |
| Sep 30, 2024 | 166,000.00 |
| Jun 30, 2024 | 696.64 Mn |
| Mar 31, 2024 | 568.56 Mn |
| Dec 31, 2023 | -24,000.00 |
| Sep 30, 2023 | -374.89 Mn |
| Jun 30, 2023 | -350.35 Mn |
| Mar 31, 2023 | 534.11 Mn |
| Dec 31, 2022 | -1.18 Mn |
| Sep 30, 2022 | -271.50 Mn |
| Jun 30, 2022 | -245.38 Mn |
| Mar 31, 2022 | 461.39 Mn |
| Dec 31, 2021 | -168,000.00 |
| Sep 30, 2021 | -22,000.00 |